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ABSTRACT 
Adjuvant chemotherapy (ACT) for stage III colon cancer is well-established. This 
study aimed to explore determinants of ACT use and between-hospital variation within the 
English National Health Service. 
11,932 patients (diagnosed 2014-2017) with pathological stage III colon cancer in the 
English NHS were identified from the National Bowel Cancer Audit. Records were linked to 
Systemic Anti-Cancer Therapy and Hospital Episode Statistics databases. 
Multi-level logistic regression analyses were performed to estimate independent 
factors for ACT use including age, sex, deprivation, comorbidities, performance status, ASA, 
surgical urgency, surgical access, TNM staging, re-admission and hospital-level factors 
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(University teaching hospital, on-site chemotherapy and high-volume centre). A random 
intercept was modelled for each English NHS hospital (n=142). 
Between-hospital variation was explored using funnel plot methodology. Fully-
adjusted random-intercept models were fitted separately in young (<70 years) and elderly 
(≥70 years) patients, and intra-class correlation coefficients estimated. 
60.7% of patients received ACT. Age was the strongest determinant. Compared to 
patients <60 years, those aged 60-64 (adjusted odds ratio (aOR) 0.76 (95% CI 0.63-0.93), 65-
69 (aOR 0.63 (0.54-0.74), 70-74 (aOR 0.53 (95% CI 0.44-0.62)), 75-79 (aOR 0.23 (0.19-
0.27)) and ≥80 (aOR 0.05 (0.04-0.06)) were significantly less likely to receive ACT. 
With adjustment for other factors, ACT use was more likely in patients with higher 
socioeconomic status, fewer comorbidities, better performance status, lower ASA grade, 
advanced disease, elective resections, laparoscopic procedures, and no unplanned 
readmissions. Hospital-level factors were non-significant.   
The observed proportions of ACT administration in the young and elderly were 46%-
100% (80% hospitals 74%-90%) and 10%-81% (80% hospitals 33%-65%) respectively. 
Risk-adjustment did not reduce between-hospital variation. Despite adjustment, age 
accounted for 9.9% (7.2%-13.4%) of between-hospital variation in the elderly compared to 
2.7% (1.2%-5.7%) in the young.  
There is significant between-hospital variation in ACT use for stage III colon cancer, 
especially for older patients. Advanced age alone seems to be a greater barrier to ACT use in 





In England, approximately 19,000 cases of colon cancer are diagnosed annually.[1] 
Of these, 25% present with stage III disease and up to 40% of these develop recurrence after 
curative resection.[2]  
The benefits of adjuvant chemotherapy (ACT) for stage III colon cancer are well-
established.[3] Current guidelines in England recommend ACT in fit patients.[4] A recent 
audit report suggested only 57% of patients with stage III colorectal cancer (CRC) received 
ACT in the English National Health Service (NHS) with variation between regions (41% to 
68%).[1] ACT has been shown to improve overall 5-year relative survival by up to 33%, 
meaning underutilisation is significant.[5] 
Studies outside the United Kingdom (UK) have demonstrated similar rates of ACT 
use for stage III colon cancer.[6-8] Most studies have been conducted in the United States but 
often include single-state cancer registries or SEER-Medicare data (only insured patients 
aged 65 or older) which limits their representativeness. Studies using National Cancer 
Database data are most representative but still only include one third of inpatient hospitals.[9]  
Current International Society of Geriatric Oncology (SIOG) consensus 
recommendations advise fluoropyrimidine monotherapy for patients aged 70 years or older, 
with oxaliplatin therapy of uncertain benefit.[10] Age has consistently been shown as one of 
the strongest determinants of ACT use[6-8,11] which is particularly important in the context 
of an ageing population. There has been a recent focus on the under-treatment of elderly 
patients with cancer.[12,13] 
Variation in chemotherapy use between hospitals and regions has been observed but 
the reasons underlying this are not well understood.[14,15] No previous studies have 
investigated explanations for between-hospital variation in chemotherapy use. Understanding 
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these reasons is crucial in reducing unwarranted variation, facilitating increased rates of ACT 
use, and potentially improving survival outcomes.  
We linked the National Bowel Cancer Audit (NBOCA)[16], a unique resource 
involving prospective mandatory data collection for all newly diagnosed CRC patients in the 
English NHS, to chemotherapy and hospital administrative databases. This enabled us to 
establish current national practice in the use of ACT in stage III colon cancer, explore 
determinants for use of ACT according to patient and hospital-level characteristics, establish 
between-hospital variation and investigate possible reasons for this. 
Our dataset includes all centres providing colon cancer treatment in the English NHS 
with no exclusions based on insurance status, socioeconomic status or age, and with case 
ascertainment >95% of all adults diagnosed with primary colon cancer in England. This ‘real-
world’ contemporary data from the English NHS, where care is free at the point of need, 
provides an effective platform for investigating hospital-level variation. 
 
MATERIALS & METHODS 
Study population 
National Bowel Cancer Audit (NBOCA) 
Patients aged 18 years or older with a primary diagnosis of colon cancer, according to 
ICD-10 codes (International Classification of Diseases, 10th revision), between 1 April 2014 
and 31 March 2017 who had undergone major resection with pathological stage III disease 
were identified in the NBOCA database. Cancers of the appendix were excluded.Identified 
patients were linked to the Admitted Patient Care records in Hospital Episode Statistics 




The linked NBOCA-HES-APC cohort included 11,932 patients deemed potentially 
eligible for ACT from 142 English NHS hospitals (Figure 1). Patients diagnosed within a 
private hospital and undergoing major resection in an NHS hospital are included. Patients 
diagnosed and treated entirely in the private sector are not captured, however, represent a 
small number of patients.  
604 patients (5%) died within 4 months of surgery. This small proportion was retained 
in the main analysis because it is unlikely to significantly affect the results and provides a full 
representation of ACT use, including all patients diagnosed with stage III disease. 
 
SACT (Systemic Anti-cancer Therapy) database 
The SACT database is the world’s first comprehensive, dedicated chemotherapy 
dataset which mandated submission of data by all English NHS providers of chemotherapy in 
any inpatient, day case, outpatient or community setting, from April 2014.[18] SACT data 
was available until 30 September 2017, providing a minimum of 4 months of follow-up from 
surgery for all patients. SACT provides the regimen start date and regimen name.  
 
Identification of patients receiving ACT 
Eligible patients were considered to have received ACT if their NBOCA record linked 
to a SACT record demonstrating use of any potentially curative colonic chemotherapy 
regimen within 4 months after surgery. The proportion of patients receiving each type of 
regimen is listed within Supplementary Table 1.  
We validated ACT use utilising HES-APC. All inpatient admissions for each patient 
within 4 months after surgery were searched for relevant chemotherapy codes (OPCS-4 
(Office of Population Censuses and Surveys Classification of Surgical Operations and 




Patient and hospital characteristics 
Data regarding sex, age, pathological staging (TNM staging), operative date, surgical 
urgency, performance status,[19] ASA grade,[20] and surgical access were obtained from 
NBOCA. Comorbidities, socioeconomic status and 30-day unplanned readmission data were 
obtained from HES-APC. The Royal College of Surgeons’ Charlson comorbidity score was 
used for diagnostic codes identified in the year preceding colon cancer diagnosis.[21]  
SIOG recommendations use 70 years as the distinction between elderly and non-
elderly; the rationale for our age cut-off.[10] Patients were recorded as having an unplanned 
30-day readmission if HES-APC showed an emergency admission within 30 days of surgery. 
Socioeconomic status was derived from the Index of Multiple Deprivation (IMD) 
which ranks 32,482 geographical areas of England according to their level of deprivation 
across seven domains.[22] Patients are allocated to an IMD quintile (IMDQ) based on the 
national ranking of the area corresponding to their postcode.  
In the English NHS, hospital-level care is provided by ‘hospital Trusts’. These may 
consist of an individual hospital or several hospitals combined. We use ‘hospital’ to refer to 
these hospital Trusts. Hospital-level characteristics were derived from the hospital carrying 
out the surgery according to NBOCA. University teaching hospitals were identified from the 
Association of United Kingdom University Hospitals.[23] On-site chemotherapy presence 
was collected in an annual national NBOCA survey of CRC services.[24] Hospitals were 
categorised as high-volume if they performed on average >100 CRC resections per year as 




Final cohort  
Table 1 shows the proportion of the 11,932 patients identified in SACT and/or HES-
APC as receiving ACT. For the main analysis, 7,239 patients with a chemotherapy record in 
either database were considered to have received ACT. 8.0% (579/7,239) of these were 
identified from HES-APC alone. 
 
Statistical Analysis 
Multivariable random-effects logistic regression was used to estimate associations 
between ACT use and the patient and hospital characteristics described above. A random 
intercept was modelled for each hospital to account for possible clustering of results within 
hospitals. Subgroup analyses were performed in the same manner to evaluate patient and 
hospital characteristics separately in the young (<70 years) and elderly (≥70 years).  
Missing values for determinants were imputed with multiple imputation using chained 
equations, creating ten datasets and using Rubin’s rules to combine the estimated odds ratios 
across the datasets.[25] Multiple imputation was used to impute all missing data for 
socioeconomic status, RCS Charlson score, performance status, ASA grade, urgency of 
resection, surgical access and pathological T-stage. 
Hospital-level variation in ACT use was explored visually using funnel plots to 
establish whether the between-hospital variation in the proportion of patients receiving ACT 
was greater than expected by chance alone.[26] Separate fully-adjusted funnel plots were 
generated for all patients, patients aged below 70 years only, and patients aged 70 years or 
older only, to explore whether between-hospital variation was associated with age. All 142 
hospitals had 10 or more patients eligible for ACT overall and were included in the funnel 
plot for all patients. 135 hospitals had 10 or more patients aged below 70 years and 10 or 
more patients aged 70 years or older, and were included in the young and elderly funnel plots. 
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The intra-class correlation coefficient (ICC) was used to quantify the between-
hospital variation in a fully-adjusted random-intercept logistic regression model. The ICC 
represents the proportion of the total variance that is between hospitals, despite adjustment 
for all other determinants, with larger values demonstrating greater between-hospital 
variation.  
To identify sources of between-hospital variation, the ICC was estimated in 8 strata of 
the cohort: young (<70 years) versus elderly (≥70 years); non-comorbid (Charlson=0) versus 
comorbid (Charlson≥1); performance status 0-1 versus performance status ≥2; and low 
(IMDQ 1-2) versus high (IMDQ 3-5) socioeconomic status. One risk-adjustment model was 
estimated in all patients and used for each stratum. We compared the ICC between strata 
using an independent samples t-test to calculate two-tailed p-values (0.05 significance level).    
All statistical analyses were conducted using STATA® version 15.1 (StataCorp, 
College Station, Texas, USA). 
 
RESULTS 
Determinants of ACT use 
7,239 patients (60.7%) were identified as having received ACT (Table 2). The 
strongest predictor for ACT use was age, despite adjustment for all other factors. Compared 
to 85.3% of patients aged <60 years who received ACT, 80.7%, 76.3%, 71.3%, 50.2% and 
18.6% of those aged 60-64 years (aOR 0.76 (95% CI 0.63-0.93), 65-69 years (aOR 0.63 
(95% CI 0.54-0.74), 70-74 years (aOR 0.53 (95% CI 0.44-0.62)), 75-79 years (aOR 0.23 
(0.19-0.27)) and ≥80 years (aOR 0.05 (0.04-0.06)) received ACT respectively. Although the 
use of ACT decreased with age, a substantial proportion of patients aged below 70 years did 
not receive ACT. 
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Other patient characteristics associated with increased ACT use included higher 
socioeconomic status, fewer comorbidities, better performance status, and lower ASA grade. 
ACT use was also more likely in the multivariable model  in patients who had an elective 
procedure, had undergone laparoscopic resection, had more advanced disease (T3/T4 or N2 
disease), and did not have an unplanned readmission.  
Subgroup analyses of patient and hospital-level factors were performed for the young 
(<70 years) and elderly (≥70 years) (Supplementary Table 3 (a) and (b)). The multivariable 
results were largely similar to those of the whole sample except that females were less likely 
to receive ACT if they were old, adjusting for other factors.  
Further analysis was carried out on patients aged 70 years or older to investigate ACT 
use in different age strata according to comorbidities, performance status and ASA grade 
(Supplementary Table 4). A downward trend in ACT use can be observed with increasing age 
for each factor, for example, 75% of 70-74 year olds with performance status 0/1 received 
ACT versus 25% of those aged 80 years or older also with performance status 0/1.  
 
Variation between hospitals 
ACT use varied substantially between hospitals. The observed hospital proportion of 
chemotherapy administered ranged from 26% to 86%. Amongst patients less than 70 years, 
observed proportions ranged from 46% to 100% (80% of hospitals 74% to 90%). In 
comparison, amongst patients aged 70 years or older, observed proportions ranged from 10% 
to 81% (80% of hospitals 33% to 65%).  
Adjustment for factors included in the multivariable model did not reduce hospital 
variation. Assuming differences arise from random errors alone, the expected number of 
hospitals outside the inner (95%) and outer (99.8%) funnel limits for all analyses is 7 and 0.3 
respectively. For patients less than 70 years, 10 hospitals lay outside the inner funnel limits 
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and 0 hospitals outside the outer limits, compared to 21 and 5 hospitals in patients aged 70 
years or older, respectively (Figure 2).   
The ICC for patients less than 70 years was 2.7% (95% CI 1.2%-5.7%) compared to 
9.9% (95% CI 7.2%-13.4%) in patients aged 70 years or older, which demonstrates a 
significantly greater proportion of the total variance to be between hospitals in the elderly 
compared to younger patients (p=<0.001). Differences in ICCs by comorbidity, performance 
status and socioeconomic status were not statistically significant (Figure 3). 
 
DISCUSSION 
This large, representative national study has firstly demonstrated significant variation 
in the use of ACT for patients with stage III colon cancer within the English NHS. Secondly, 
it has shown that age has a significant effect on ACT use which persists despite risk-
adjustment suggesting underuse of ACT in elderly patients. A significantly greater proportion 
of between-hospital variation is found in the elderly, indicating that age is a greater barrier to 
ACT use in some hospitals compared to others. Thirdly, we identified socioeconomic status 
as a determinant of ACT use, despite case-mix adjustment. 
This is the first population-based study evaluating the use of ACT for stage III colon 
cancer in England. Our finding that 60% of patients received ACT is similar to figures found 
elsewhere. A recent large US study of 124,008 patients with stage III colon cancer suggested 
that 66% received ACT between 2003-2011.[7] Two Canadian studies reported that 50% of 
patients received chemotherapy, despite a healthcare system where access to treatment is 
free.[27,28] Within Europe, similar ACT rates have been found in Germany (65%)[29], 
France (65.1%)[30], Italy (64.6%)[30], Belgium (68%)[2], Sweden (55%)[2] and the 
Netherlands (61%).[2]  
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Our multivariable analysis demonstrated findings that are largely consistent with 
those expected. Although we would expect age to influence ACT use, the magnitude of the 
effect despite risk-adjustment was marked and most apparent in those aged 75 years or older. 
Patients included in this study have been deemed fit enough to tolerate a major colonic 
resection suggesting that many have the potential to be candidates for adjuvant 
chemotherapy, although post-operative status and life expectancy also need to be taken in to 
consideration.   
Previous studies are in agreement with our finding that socioeconomic status is a 
determinant of ACT use.[31,32] Suggested explanations include delayed presentation,[33] 
increased comorbidities,[32] and reduced health-seeking behaviours.[31] Socioeconomically 
deprived patients in our cohort tended to be younger and more comorbid, and had more often 
undergone emergency resection (results not shown). Education and targeted screening may 
help facilitate ACT use in this group by reducing emergency presentations. However, 
socioeconomic status was a significant determinant despite risk-adjustment suggesting it is a 
barrier to ACT use in its own right. 
Comorbidity has been associated with ACT use,[11] but performance status and ASA 
grade have not previously been reported. These three determinants have been shown to have 
limited correlation in CRC patients suggesting that they represent independent measures of 
patient well-being and supporting their inclusion in our model.[34]  
As described previously, we have demonstrated that laparoscopic surgery and 
unplanned readmissions are significant determinants for ACT.[2,35-37] Laparoscopic surgery 
may increase ACT use because it is associated with fewer complications, faster recovery and 
reduced inflammatory response. Unplanned readmissions prolong hospital stay which may 
make the timely use of ACT more difficult.  
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Patients undergoing emergency surgery were less likely to receive ACT. Previous 
studies have shown conflicting evidence.[30,38] An explanation for emergency patients being 
less likely to receive ACT is that they are at increased risk of experiencing post-operative 
complications and are more likely to have stomas formed. 
Hospital-level characteristics, including being a university teaching hospital or having 
on-site chemotherapy facilities, were not associated with ACT use. A Scottish study 
demonstrated the significance of on-site chemotherapy facilities but its results were limited 
because of the absence of staging information.[39]  
Other hospital-level factors which we were unable to measure in this study but may 
influence between-hospital variation in ACT use include rurality, distance to the nearest 
chemotherapy centre, and oncologist characteristics such as length of practice and volume of 
consultations for patients with colorectal cancer.[37] A systematic review evaluating 
geographical variation in access to chemotherapy within the UK suggested that healthcare 
boundaries, such as which English ‘cancer alliance’ a hospital lies within, rather than ‘natural 
geographic factors’ were most important. The influence of commissioners, policy-makers and 
individual providers are therefore important.[14] Although most marked in the elderly, 
variation was also present in the young with up to 55% of patients less than 70 years not 
receiving ACT in some hospitals. The observed variation in ACT use is important because it 
suggests that not all patients are receiving optimal adjuvant therapy, particularly those aged 
70 years or older.  
Wennberg described the concept of ‘unwarranted variation’ whereby variation in the 
use of health care services cannot be explained by variation in patient illness or patient 
preference.[40] Unwarranted variation may consist of overtreatment or undertreatment. 
Underlying factors can include clinician and patient preferences and attitudes, availability of 
particular resources, and discrepancies in the treatment of certain patient groups, for example 
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the elderly and those from a lower socioeconomic background, consistent with our study 
findings.[41]  
Within this study, we accounted for case-mix differences and it is unlikely that the 
between-hospital variation after adjustment can be fully explained by patient preferences. 
This suggests that ‘unwarranted variation’ exists in the use of ACT and highlights the need 
for a more consistent use of ACT resources in the English NHS.  
Patient choice is an important and complex factor determining the use of 
chemotherapy. Patient-related factors influencing decision-making for cancer treatments are 
extensive and can include social, cognitive and psychological issues. Physician-related 
factors such as poor communication, lack of information or distrust in the patient-clinician 
relationship are also important. Clinician recommendations have been found to be the most 
important influence in patients’ decision-making pathways.[42]  
Qualitative studies support our suggestion that unwarranted variation (as identified in 
this study), especially in the elderly, may be attributable to varying clinician practice. One 
study showed that clinician recommendations varied more widely according to increasing 
comorbidity in the elderly compared to the young.[43] Other studies have highlighted bias in 
clinician decision-making related to advancing age.[44,45]  
Given these findings clinicians should recognise the importance of their input in to 
shared decision-making and be educated in this process. Patients should also be educated 
about the benefits and risks of adjuvant chemotherapy and support provided as necessary to 
facilitate informed decision-making and overcome potential barriers. Specialist nurses may 
provide support in this area.  
SIOG recommends the use of comprehensive geriatric assessments (CGAs) which 
facilitate the formation of individualised treatment plans. There is evidence supporting their 
use for chemotherapy decision making.[46,47] 
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Clinical trials need to be enriched through population with more elderly, frail 
patients.[48] Real-world data can be used to evaluate outcomes in groups under-represented 
by trials. Both of these can be used to support the development of elderly-specific guidelines 
and associated educational resources to aid clinical decision making and reduce the observed 
variation in practice. 
The National Bowel Cancer Audit will be implementing a new process measure 
pertaining to adjuvant chemotherapy use for stage III colon cancer. It will report figures for 
England at a hospital-level. Other healthcare providers should consider similar evaluations of 
practice which highlight ‘unwarranted variation’, facilitate quality improvement and allow 
monitoring of ACT rates relative to national benchmarking.  
There is robust evidence that ACT improves outcomes. Underuse could therefore be a 
contributing factor to England having lower survival rates for colon cancer compared to other 
European countries. A recent study suggested that the survival deficit in England is partly 
attributable to shortfalls in treatment with a steep declining age gradient in the probability of 
receiving colonic resection (particularly those aged 75 years or older) compared to Denmark, 
Norway and Sweden.[49]  Our results indicate that similar patterns may exist for ACT use.    
There were several limitations to our study. Firstly, we considered that patients had 
received ACT if there was evidence of colonic chemotherapy, irrespective of regimen, within 
the first 4 months after surgery. This approach is supported by the observation that 
approximately 96% of observed regimens were in keeping with standard practice 
(Supplementary Table 1).[4] The remainder could represent atypical practice or palliative 
treatment. We were also unable to obtain regimen details for patients captured in HES-APC 
alone. However, a sensitivity analysis performed using SACT data alone to identify patients 
who had received ACT produced similar results (5 hospitals were excluded from this analysis 
as they captured <50% of ACT compared to HES-APC). 
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We could not determine chemotherapy refusal rates but these have been reported to be 
around 10%[50] and some studies used an offer of chemotherapy as their numerator which 
did not substantially change their results.[6] Refusal is therefore unlikely to completely 
explain ACT underuse. 
Finally, we were unable to capture all factors which may influence ACT use such as 
social support, nutrition and cognitive function. Neither could we measure the severity of 
individual comorbidities, although we captured performance status and ASA grade. 
Our study includes a large representative cohort of patients with stage III colon cancer 
identified in all hospitals providing colon cancer care in the English NHS. SACT provides a 
unique data source, with data captured directly by chemotherapy providers. Linkage of 
multiple national datasets facilitated further validation of the data. 
 
CONCLUSIONS 
Our study represents an evaluation of current practice in the use of ACT for stage III 
colon cancer in the English NHS. We found considerable variation in ACT use between 
hospitals, most prominently in elderly patients. We also demonstrated that, despite case-mix 
adjustment, there is an association between socioeconomic status and ACT use suggesting 
possible inequalities in access to ACT. Finally, we highlighted the importance of post-
operative recovery in the use of ACT. 
We envisage that these findings will be applicable to health care settings outside of 
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Table 1 – Proportion of patients identified as having ACT according to the SACT and/or 
HES-APC databases (row and column percentages given). 
 
 




according to HES-APC 
 
Yes No Total 
Yes 4,742 (89.1%) 579 (10.9%) 5,321 
(71.2%) (11.0%) 
No 1,918 (29.0%) 4,693 (71.0%) 6,611 
(28.8%) (89%) 
































Table 2 – Distribution of patient and hospital characteristics and their effect on ACT use. 
 Total (%)  n=11,932 Received ACT (%) n=7,239 p-value (Ҳ2) Adjusted odds ratios (95% CI) p-value 
Sex   0.009  0.368 
Male  6,227 (52.2) 3,847 (61.8)  1.0  
Female 5,705 (47.8) 3,392 (59.5)  0.96 (0.88-1.05)  
Age (years)   <0.001  <0.001 
<60 2,267 (19.0) 1,933 (85.3)  1.0  
60-64 1,320 (11.1) 1,065 (80.7)  0.76 (0.63-0.93)  
65-69 1,758 (14.7) 1,341 (76.3)  0.63 (0.54-0.74)  
70-74 1,996 (16.7) 1,423 (71.3)  0.53 (0.44-0.62)  
75-79 1,976 (16.6) 992 (50.2)  0.23 (0.19-0.27)  
≥80 2,615 (21.9) 485 (18.6)  0.05 (0.04-0.06)  
Socioeconomic status (IMDQ)   0.149  0.002 
1 (most deprived) 1,815 (15.2) 1,061 (58.5)  1.0  
2 1,990 (16.7) 1,193 (60.0)  1.11 (0.93-1.33)  
3 2,603 (21.8) 1,602 (61.5)  1.29 (1.10-1.50)  
4 2,742 (23.0) 1,666 (60.8)  1.22 (1.05-1.42)  
5 (least deprived) 2,759 (23.1) 1,708 (61.9)  1.36 (1.15-1.60)  
Missing* 23 9    
RCS Charlson score   <0.001  <0.001 
0 6,428 (53.9) 4,425 (68.8)  1.0  
1 3,344 (28.0) 1,913 (57.2)  0.80 (0.72-0.90)  
≥2 1,524 (12.8) 570 (37.4)  0.50 (0.44-0.58)  
Missing* 636 331    
Performance status   <0.001  <0.001 
0 4,989 (41.8) 3,724 (74.6)  1.0  
1 3,424 (28.7) 1,974 (57.7)  0.83 (0.73-0.95)  
2 1,319 (11.1) 521 (39.5)  0.54 (0.45-0.65)  
≥3 441 (3.7) 67 (15.2)  0.17 (0.13-0.24)  
Missing* 1,759 953    
ASA fitness grade   <0.001  <0.001 
I 1,469 (12.3) 1,182 (80.5)  1.0  
II 6,091 (51.1) 4,226 (69.4)  0.95 (0.81-1.12)  
III 3,272 (27.4) 1,339 (40.9)  0.56 (0.50-0.63)  
IV or V 365 (3.1) 72 (19.7)  0.24 (0.18-0.32)  
Missing* 735 420    
Urgency of resection   <0.001  0.001 
Elective/scheduled 9,005 (75.5) 5,668 (62.9)  1.0  
Emergency/urgent 2,908 (24.4) 1,560 (53.7)  0.80 (0.71-0.91)  
Missing 19 11    
Surgical access   <0.001  <0.001 
Open 4,885 (40.9) 2,689 (55.1)  1.0  
Laparoscopic-converted 971 (8.1) 580 (59.7)  1.0 (0.83-1.19)  
Laparoscopic 6,035 (50.6) 3,947 (65.4)  1.28 (1.14-1.44)  
Missing* 41 23    
Pathological T-stage   0.001  0.006 
T1 241 (2.0) 155 (64.3)  1.0  
T2 706 (5.9) 471 (66.7)  1.35 (0.96-1.88)  
T3 5,976 (50.1) 3,639 (60.9)  1.47 (1.10-1.95)  
T4 5,004 (41.9) 2,971 (59.4)  1.61 (1.20-2.17)  
Missing* 5 3    
Pathological N-stage   <0.001  <0.001 
N1 7,620 (63.9) 4,464 (58.6)  1.0  
N2 4,312 (36.1) 2,775 (64.4)  1.31 (1.18-1.46)  
30-day readmission    0.001  <0.001 
No 10,921 (91.5) 6,675 (61.1)  1.0  
Yes 1,011 (8.5) 564 (55.8)  0.66 (0.56-0.77)  
University teaching hospital   0.595  0.475 
No 8,880 (74.4) 5,375 (60.5)  1.0  
Yes 3,052 (25.6) 1,864 (61.1)  0.93 (0.75-1.15)  
On-site chemotherapy facilities   0.927  0.906 
No 1,336 (11.2) 809 (60.6)  1.0  
Yes 10,596 (88.8) 6,430 (60.7)  0.99 (0.81-1.21)  
High volume centre   0.232  0.864 
No 2,643 (22.2) 1,577 (59.7)  1.0  
Yes 9,289 (77.9) 5,662 (61.0)  1.02 (0.81-1.28)  
21 
 










Figure 2 – Funnel plots demonstrating the proportion of patients undergoing major resection 
with pathological stage III colon cancer who received ACT at each hospital, adjusted for all 








Figure 3 – the proportion of the total variation that is between hospitals according to age, 
comorbidities, performance status and socioeconomic status.  
 
 
